On November 18, Ionis Pharmaceuticals fell 5.11% in Regular Trading to $26.58 per share, with turnover of $52.2608 million.
The latest catalyst was the European Commission approval of Tryngolza for adults with severe hypertriglyceridemia, expanding beyond its prior EU approval in familial chylomicronemia syndrome. The drug had met the primary endpoint in two phase 3 trials, lowering triglycerides and reducing acute pancreatitis events versus placebo, while Sobi holds exclusive commercialization rights outside the US except Canada and China.
Even so, the market remained focused on commercialization pressure after Ionis previously cut full-year Tryngolza sales guidance to $50 million from $100 million to $110 million. That overhang persisted despite third-quarter revenue rising 55% year over year to $243 million and net loss narrowing to $0.66 per share, both better than consensus expectations, while the company maintained total revenue guidance of $875 million to $900 million.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments